Cyted’s unique data-driven test monitors patients suffering from Barrett’s oesophagus – who risk developing oesophageal cancer – ensuring that cancer can be quickly detected and treated, or even treated at the pre-cancerous stage to stop it ever progressing.
The early cancer test allows patients to swallow a capsule which collects cells from the oesophagus in a process that takes just ten minutes and can be delivered in the community. This technology is more comfortable and more accessible than conducting endoscopies – the current standard of care for monitoring Barrett’s oesophagus patients.
Cyted then digitises cell samples which are analysed by its pathologists. They identify biomarkers – a measurable biological indicator of the likelihood of a cancer developing. Patients are advised of the risk of developing oesophageal cancer and directed for further tests and treatment where necessary.
Oesophageal cancer remains a pressing public health priority, with late diagnoses leading to poor survival rates. Cyted’s highly effective diagnostic pathway to detect early-stage oesophageal cancer can reduce NHS backlogs and relieve pressures on endoscopy services.
The test is currently used in more than 50 hospitals in England and Scotland and is being trialled in community settings from August 2022, including in GP surgeries. The NHS has provided £500,000 of funding to pilot testing in community care across North-West England.
MARCEL GEHRUNG, CEO and co-founder of Cyted said “This milestone shows the difference that our test is making for many thousands of patients. This technology delivers quicker and less intrusive monitoring, freeing up NHS resources.
“The next stage will see the early cancer test used in GP clinics and community diagnostic centers. It’s exciting to see an innovation created in the UK making such a positive impact for patients. There is huge potential to build on this work to support many more patients and develop new diagnostic tests in future.”
